A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Adults With Stable Coronary Heart Disease
Stable Coronary Heart Disease
About this trial
This is an interventional treatment trial for Stable Coronary Heart Disease focused on measuring Coronary heart disease, Pharmacokinetic, Pharmacodynamics
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of stable coronary heart disease prior to screening
- Currently receiving high intensity statin(s)
Exclusion Criteria:
- Unstable cardiovascular conditions
- Any planned arterial revascularizations
- Fasting Laboratory values at screening: Triglycerides > 500 mg/dl, Low Density Lipoprotein-Cholesterol > 100 mg/dL
- Any disease or condition or laboratory value that would place the participant at an unacceptable risk.
Sites / Locations
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Placebo Comparator
Experimental
Experimental
Experimental
Experimental
Experimental
Placebo
MEDI5884 50 mg
MEDI5884 100 mg
MEDI5884 200 mg
MEDI5884 350 mg
MEDI5884 500 mg
Participants will receive subcutaneous (SC) dose of placebo (volume matched to MEDI5884) on Days 1, 31, and 61.
Participants will receive SC dose of MEDI5884 50 mg on Days 1, 31, and 61.
Participants will receive SC dose of MEDI5884 100 mg on Days 1, 31, and 61.
Participants will receive SC dose of MEDI5884 200 mg on Days 1, 31, and 61.
Participants will receive SC dose of MEDI5884 350 mg on Days 1, 31, and 61.
Participants will receive SC dose of MEDI5884 500 mg on Days 1, 31, and 61.